| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 266 | 2024 | 7244 | 19.640 |
Why?
|
| Myelodysplastic Syndromes | 75 | 2024 | 3148 | 7.390 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 47 | 2024 | 842 | 6.990 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 135 | 2024 | 16606 | 5.200 |
Why?
|
| Azacitidine | 49 | 2024 | 1218 | 4.870 |
Why?
|
| Primary Myelofibrosis | 24 | 2024 | 902 | 4.240 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 47 | 2024 | 995 | 4.240 |
Why?
|
| Protein Kinase Inhibitors | 48 | 2024 | 4963 | 3.550 |
Why?
|
| Mutation | 100 | 2024 | 15913 | 3.190 |
Why?
|
| Antineoplastic Agents | 59 | 2024 | 14653 | 3.040 |
Why?
|
| Sulfonamides | 45 | 2024 | 1918 | 2.860 |
Why?
|
| Myeloproliferative Disorders | 20 | 2024 | 881 | 2.490 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 44 | 2024 | 6986 | 2.480 |
Why?
|
| Humans | 446 | 2024 | 271636 | 2.440 |
Why?
|
| Cytarabine | 42 | 2024 | 2014 | 2.360 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 30 | 2024 | 2898 | 2.330 |
Why?
|
| Isocitrate Dehydrogenase | 14 | 2023 | 520 | 2.210 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 8 | 2022 | 183 | 2.110 |
Why?
|
| Aged | 231 | 2024 | 73421 | 2.080 |
Why?
|
| Aged, 80 and over | 137 | 2024 | 31032 | 1.970 |
Why?
|
| Middle Aged | 235 | 2024 | 90349 | 1.930 |
Why?
|
| Immunoconjugates | 7 | 2024 | 314 | 1.920 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 25 | 2024 | 2634 | 1.810 |
Why?
|
| Adult | 199 | 2024 | 81791 | 1.750 |
Why?
|
| Molecular Targeted Therapy | 16 | 2024 | 2398 | 1.750 |
Why?
|
| Antineoplastic Agents, Immunological | 11 | 2022 | 1335 | 1.730 |
Why?
|
| Remission Induction | 46 | 2023 | 3645 | 1.660 |
Why?
|
| Treatment Outcome | 116 | 2024 | 33846 | 1.640 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 6 | 2021 | 120 | 1.640 |
Why?
|
| Prognosis | 93 | 2024 | 22525 | 1.560 |
Why?
|
| Male | 223 | 2024 | 128836 | 1.550 |
Why?
|
| Hematologic Neoplasms | 10 | 2024 | 1950 | 1.550 |
Why?
|
| Nitriles | 14 | 2024 | 943 | 1.520 |
Why?
|
| Antibodies, Monoclonal, Humanized | 14 | 2023 | 3391 | 1.510 |
Why?
|
| Immunotherapy | 12 | 2023 | 3539 | 1.500 |
Why?
|
| Bone Marrow | 24 | 2024 | 2431 | 1.440 |
Why?
|
| Antimetabolites, Antineoplastic | 17 | 2024 | 1346 | 1.420 |
Why?
|
| Young Adult | 101 | 2024 | 22094 | 1.400 |
Why?
|
| Female | 218 | 2024 | 148992 | 1.400 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 10 | 2024 | 461 | 1.380 |
Why?
|
| T-Lymphocytes | 12 | 2023 | 3934 | 1.350 |
Why?
|
| Pneumonia | 5 | 2023 | 798 | 1.310 |
Why?
|
| Idarubicin | 15 | 2023 | 459 | 1.300 |
Why?
|
| Nuclear Proteins | 16 | 2024 | 3472 | 1.280 |
Why?
|
| Tumor Suppressor Protein p53 | 22 | 2023 | 3670 | 1.260 |
Why?
|
| Leukemia | 7 | 2024 | 1721 | 1.240 |
Why?
|
| Immunotoxins | 3 | 2018 | 120 | 1.210 |
Why?
|
| Neoplasm Proteins | 10 | 2021 | 3363 | 1.170 |
Why?
|
| Blast Crisis | 9 | 2022 | 587 | 1.130 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2024 | 5420 | 1.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 189 | 1.110 |
Why?
|
| Thalidomide | 5 | 2022 | 595 | 1.070 |
Why?
|
| Retrospective Studies | 89 | 2024 | 39731 | 1.060 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 4 | 2023 | 95 | 1.060 |
Why?
|
| Recurrence | 32 | 2024 | 4884 | 1.040 |
Why?
|
| Neoplasm, Residual | 24 | 2023 | 1740 | 1.010 |
Why?
|
| Pyridazines | 10 | 2024 | 319 | 1.010 |
Why?
|
| Neoplasms, Second Primary | 10 | 2022 | 1387 | 1.000 |
Why?
|
| Pyrazoles | 12 | 2024 | 1543 | 0.970 |
Why?
|
| Leukemia, Promyelocytic, Acute | 6 | 2021 | 439 | 0.970 |
Why?
|
| Philadelphia Chromosome | 14 | 2023 | 834 | 0.970 |
Why?
|
| Aniline Compounds | 6 | 2024 | 206 | 0.960 |
Why?
|
| Salvage Therapy | 15 | 2021 | 2118 | 0.940 |
Why?
|
| Survival Analysis | 40 | 2021 | 9323 | 0.920 |
Why?
|
| Febrile Neutropenia | 2 | 2024 | 74 | 0.920 |
Why?
|
| Disease-Free Survival | 47 | 2023 | 10259 | 0.910 |
Why?
|
| Pyrimidines | 15 | 2024 | 3663 | 0.900 |
Why?
|
| Pyrrolidines | 1 | 2024 | 114 | 0.900 |
Why?
|
| Arabinonucleosides | 6 | 2017 | 458 | 0.890 |
Why?
|
| Phenylurea Compounds | 7 | 2024 | 600 | 0.880 |
Why?
|
| Survival Rate | 48 | 2024 | 12530 | 0.880 |
Why?
|
| Anemia | 5 | 2024 | 730 | 0.870 |
Why?
|
| Imidazoles | 11 | 2024 | 1055 | 0.860 |
Why?
|
| Janus Kinases | 4 | 2017 | 175 | 0.850 |
Why?
|
| Pyrazines | 5 | 2024 | 513 | 0.850 |
Why?
|
| Cladribine | 9 | 2024 | 253 | 0.850 |
Why?
|
| Antibodies, Monoclonal | 10 | 2022 | 4495 | 0.840 |
Why?
|
| Adolescent | 71 | 2024 | 32609 | 0.820 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2024 | 2624 | 0.800 |
Why?
|
| Tandem Repeat Sequences | 8 | 2020 | 203 | 0.790 |
Why?
|
| Polycythemia Vera | 4 | 2018 | 268 | 0.780 |
Why?
|
| Induction Chemotherapy | 14 | 2023 | 671 | 0.770 |
Why?
|
| Receptors, Mitogen | 1 | 2021 | 11 | 0.770 |
Why?
|
| Chromosome Aberrations | 15 | 2024 | 2034 | 0.760 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 5 | 2023 | 205 | 0.760 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 9 | 2024 | 529 | 0.760 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 5 | 2023 | 215 | 0.760 |
Why?
|
| Gene Rearrangement | 6 | 2023 | 817 | 0.750 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2024 | 10354 | 0.730 |
Why?
|
| Staurosporine | 6 | 2022 | 149 | 0.720 |
Why?
|
| Transplantation, Homologous | 16 | 2024 | 3035 | 0.720 |
Why?
|
| Immunophenotyping | 9 | 2024 | 1729 | 0.720 |
Why?
|
| Leukemia, Lymphoid | 2 | 2019 | 290 | 0.720 |
Why?
|
| Adenine Nucleotides | 4 | 2017 | 365 | 0.720 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 163 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 8 | 2023 | 1547 | 0.710 |
Why?
|
| Proteomics | 7 | 2024 | 1436 | 0.710 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2023 | 504 | 0.710 |
Why?
|
| Aminopyridines | 3 | 2022 | 223 | 0.710 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 269 | 0.700 |
Why?
|
| Genes, p53 | 3 | 2023 | 1146 | 0.700 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2023 | 1838 | 0.700 |
Why?
|
| Drug Therapy, Combination | 7 | 2018 | 2365 | 0.680 |
Why?
|
| Immunologic Factors | 4 | 2019 | 668 | 0.680 |
Why?
|
| Biomarkers, Tumor | 10 | 2022 | 10743 | 0.670 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2021 | 595 | 0.670 |
Why?
|
| Lymphoma | 2 | 2018 | 1514 | 0.660 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 204 | 0.660 |
Why?
|
| Follow-Up Studies | 37 | 2022 | 15254 | 0.650 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 629 | 0.650 |
Why?
|
| Antibodies, Bispecific | 6 | 2024 | 274 | 0.640 |
Why?
|
| Leukemic Infiltration | 1 | 2018 | 73 | 0.630 |
Why?
|
| Fusion Proteins, bcr-abl | 8 | 2021 | 1143 | 0.630 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2018 | 71 | 0.620 |
Why?
|
| Bone Marrow Cells | 4 | 2018 | 981 | 0.620 |
Why?
|
| Cyclophosphamide | 16 | 2022 | 3231 | 0.610 |
Why?
|
| Translocation, Genetic | 6 | 2023 | 1288 | 0.610 |
Why?
|
| Karyotype | 11 | 2022 | 237 | 0.600 |
Why?
|
| Drug Administration Schedule | 15 | 2021 | 3538 | 0.600 |
Why?
|
| Niacinamide | 4 | 2015 | 427 | 0.600 |
Why?
|
| Antibodies | 1 | 2021 | 819 | 0.600 |
Why?
|
| Aminoglycosides | 4 | 2022 | 235 | 0.590 |
Why?
|
| bcl-X Protein | 2 | 2023 | 199 | 0.590 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2017 | 19 | 0.590 |
Why?
|
| Dasatinib | 10 | 2024 | 881 | 0.580 |
Why?
|
| Vincristine | 13 | 2022 | 1572 | 0.570 |
Why?
|
| Leukemia, Myeloid | 6 | 2019 | 994 | 0.570 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2017 | 169 | 0.570 |
Why?
|
| Receptors, Immunologic | 1 | 2018 | 318 | 0.560 |
Why?
|
| Precision Medicine | 2 | 2024 | 1206 | 0.560 |
Why?
|
| Maintenance Chemotherapy | 5 | 2024 | 224 | 0.560 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 272 | 0.550 |
Why?
|
| Programmed Cell Death 1 Receptor | 8 | 2023 | 1089 | 0.540 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 250 | 0.540 |
Why?
|
| Eosinophilia | 1 | 2018 | 188 | 0.530 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 50 | 0.520 |
Why?
|
| Aspergillosis | 1 | 2017 | 249 | 0.510 |
Why?
|
| Kaplan-Meier Estimate | 24 | 2021 | 6266 | 0.510 |
Why?
|
| Clinical Trials as Topic | 10 | 2022 | 3852 | 0.500 |
Why?
|
| Morpholines | 1 | 2016 | 296 | 0.490 |
Why?
|
| Cost of Illness | 1 | 2018 | 505 | 0.490 |
Why?
|
| Vidarabine | 11 | 2022 | 1383 | 0.490 |
Why?
|
| Anemia, Aplastic | 3 | 2024 | 233 | 0.470 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2014 | 25 | 0.470 |
Why?
|
| Leukocytosis | 1 | 2014 | 115 | 0.470 |
Why?
|
| Neoplasms | 13 | 2023 | 15903 | 0.470 |
Why?
|
| Leukapheresis | 1 | 2014 | 166 | 0.470 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2024 | 801 | 0.470 |
Why?
|
| Gene Expression Regulation, Leukemic | 6 | 2022 | 582 | 0.450 |
Why?
|
| Uridine | 2 | 2024 | 71 | 0.450 |
Why?
|
| CTLA-4 Antigen | 4 | 2018 | 681 | 0.440 |
Why?
|
| Models, Biological | 3 | 2020 | 3223 | 0.430 |
Why?
|
| Phenotype | 4 | 2024 | 6510 | 0.430 |
Why?
|
| Immunosuppressive Agents | 5 | 2021 | 1444 | 0.430 |
Why?
|
| Harringtonines | 1 | 2013 | 93 | 0.420 |
Why?
|
| Dexamethasone | 12 | 2021 | 1496 | 0.420 |
Why?
|
| Biomarkers | 11 | 2023 | 5111 | 0.420 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 3 | 2024 | 107 | 0.420 |
Why?
|
| DNA Methylation | 10 | 2024 | 2759 | 0.410 |
Why?
|
| Hematinics | 1 | 2013 | 109 | 0.400 |
Why?
|
| Stem Cell Transplantation | 8 | 2023 | 1424 | 0.400 |
Why?
|
| Prospective Studies | 19 | 2024 | 13385 | 0.400 |
Why?
|
| Daunorubicin | 4 | 2020 | 313 | 0.390 |
Why?
|
| Ki-1 Antigen | 1 | 2012 | 186 | 0.390 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2012 | 129 | 0.390 |
Why?
|
| Propensity Score | 7 | 2022 | 775 | 0.380 |
Why?
|
| Prednisone | 1 | 2014 | 1037 | 0.380 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 1264 | 0.370 |
Why?
|
| Tumor Microenvironment | 8 | 2024 | 2999 | 0.370 |
Why?
|
| Tumor Cells, Cultured | 3 | 2022 | 5804 | 0.370 |
Why?
|
| Benzothiazoles | 3 | 2024 | 101 | 0.370 |
Why?
|
| Doxorubicin | 12 | 2022 | 3131 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2021 | 5102 | 0.360 |
Why?
|
| Thrombocythemia, Essential | 3 | 2018 | 179 | 0.360 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2012 | 235 | 0.360 |
Why?
|
| Core Binding Factors | 5 | 2022 | 113 | 0.360 |
Why?
|
| Arsenicals | 4 | 2021 | 204 | 0.360 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2023 | 461 | 0.360 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 5067 | 0.360 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2022 | 967 | 0.350 |
Why?
|
| Epigenesis, Genetic | 6 | 2023 | 1438 | 0.350 |
Why?
|
| Cyclin-Dependent Kinase 9 | 2 | 2022 | 66 | 0.340 |
Why?
|
| Clonal Evolution | 3 | 2020 | 251 | 0.340 |
Why?
|
| Benzimidazoles | 4 | 2022 | 442 | 0.340 |
Why?
|
| Imatinib Mesylate | 5 | 2019 | 1690 | 0.340 |
Why?
|
| Triazines | 2 | 2022 | 123 | 0.330 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2023 | 2473 | 0.330 |
Why?
|
| Thrombocytosis | 2 | 2021 | 142 | 0.330 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2017 | 1842 | 0.330 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2018 | 319 | 0.330 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2022 | 123 | 0.330 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 1340 | 0.320 |
Why?
|
| Skin Neoplasms | 5 | 2023 | 4888 | 0.320 |
Why?
|
| B7-H1 Antigen | 3 | 2022 | 1072 | 0.320 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 954 | 0.310 |
Why?
|
| Maximum Tolerated Dose | 6 | 2021 | 1323 | 0.310 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 475 | 0.310 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2021 | 121 | 0.310 |
Why?
|
| Age Factors | 9 | 2020 | 5509 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 4636 | 0.310 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1736 | 0.300 |
Why?
|
| Risk Assessment | 10 | 2024 | 6876 | 0.300 |
Why?
|
| Cytogenetic Analysis | 6 | 2024 | 574 | 0.300 |
Why?
|
| Sweet Syndrome | 2 | 2020 | 35 | 0.300 |
Why?
|
| Allografts | 5 | 2022 | 684 | 0.290 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2024 | 1408 | 0.290 |
Why?
|
| Proportional Hazards Models | 8 | 2023 | 5113 | 0.290 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2023 | 2314 | 0.290 |
Why?
|
| Transplantation, Haploidentical | 2 | 2019 | 159 | 0.290 |
Why?
|
| Osteomyelitis | 2 | 2008 | 259 | 0.290 |
Why?
|
| Disease Progression | 12 | 2024 | 6905 | 0.290 |
Why?
|
| Withholding Treatment | 2 | 2019 | 156 | 0.290 |
Why?
|
| Janus Kinase 2 | 7 | 2019 | 754 | 0.290 |
Why?
|
| Methotrexate | 5 | 2020 | 1027 | 0.280 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 12008 | 0.280 |
Why?
|
| Radiotherapy | 1 | 2014 | 1858 | 0.280 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 2 | 2017 | 114 | 0.270 |
Why?
|
| Azetidines | 2 | 2024 | 88 | 0.260 |
Why?
|
| Rituximab | 5 | 2020 | 1588 | 0.260 |
Why?
|
| Risk Factors | 18 | 2023 | 18016 | 0.260 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 7 | 2022 | 770 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 2672 | 0.250 |
Why?
|
| Thrombocytopenia | 3 | 2021 | 871 | 0.250 |
Why?
|
| Spinal Cord Diseases | 2 | 2017 | 90 | 0.250 |
Why?
|
| Cohort Studies | 10 | 2022 | 9467 | 0.250 |
Why?
|
| Dendritic Cells | 5 | 2023 | 1110 | 0.250 |
Why?
|
| Transplantation Conditioning | 5 | 2021 | 2359 | 0.250 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2021 | 686 | 0.250 |
Why?
|
| B-Lymphocytes | 4 | 2024 | 1427 | 0.250 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2023 | 100 | 0.240 |
Why?
|
| Staphylococcal Infections | 2 | 2008 | 682 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2022 | 233 | 0.240 |
Why?
|
| Transcription Factors | 6 | 2024 | 5504 | 0.240 |
Why?
|
| Incidence | 8 | 2024 | 5856 | 0.240 |
Why?
|
| Animals | 20 | 2024 | 62757 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2024 | 2349 | 0.240 |
Why?
|
| Antigens, CD7 | 1 | 2024 | 30 | 0.230 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2005 | 122 | 0.230 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 1719 | 0.230 |
Why?
|
| Chromosome Deletion | 3 | 2023 | 1055 | 0.230 |
Why?
|
| Tretinoin | 5 | 2021 | 621 | 0.230 |
Why?
|
| Glutaminase | 1 | 2024 | 71 | 0.230 |
Why?
|
| Hydroxyurea | 3 | 2022 | 223 | 0.230 |
Why?
|
| Enzyme Inhibitors | 3 | 2024 | 1965 | 0.230 |
Why?
|
| Drug Discovery | 2 | 2017 | 331 | 0.230 |
Why?
|
| Chromosome Inversion | 2 | 2023 | 191 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 3171 | 0.220 |
Why?
|
| Staphylococcus aureus | 2 | 2008 | 563 | 0.220 |
Why?
|
| Histone Demethylases | 2 | 2023 | 145 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 1136 | 0.220 |
Why?
|
| Oxides | 4 | 2021 | 212 | 0.220 |
Why?
|
| Disease Management | 4 | 2021 | 1111 | 0.220 |
Why?
|
| Cell Line, Tumor | 13 | 2024 | 14868 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 5209 | 0.210 |
Why?
|
| Platelet Count | 4 | 2018 | 491 | 0.210 |
Why?
|
| Apoptosis | 10 | 2023 | 7834 | 0.210 |
Why?
|
| DNA Mutational Analysis | 4 | 2017 | 2365 | 0.210 |
Why?
|
| Nucleosides | 1 | 2022 | 63 | 0.210 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 101 | 0.210 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 148 | 0.200 |
Why?
|
| Biology | 1 | 2022 | 76 | 0.200 |
Why?
|
| Flow Cytometry | 6 | 2024 | 3077 | 0.200 |
Why?
|
| Chromosomes | 1 | 2023 | 324 | 0.200 |
Why?
|
| Graft vs Host Disease | 4 | 2021 | 2804 | 0.200 |
Why?
|
| Drug Combinations | 1 | 2024 | 634 | 0.200 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2022 | 71 | 0.200 |
Why?
|
| Hematology | 1 | 2023 | 99 | 0.200 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 73 | 0.200 |
Why?
|
| Dioxygenases | 3 | 2021 | 171 | 0.200 |
Why?
|
| Acute Disease | 7 | 2023 | 2510 | 0.200 |
Why?
|
| Congenital Abnormalities | 1 | 2005 | 280 | 0.200 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2023 | 135 | 0.200 |
Why?
|
| ras Proteins | 3 | 2022 | 802 | 0.190 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2022 | 105 | 0.190 |
Why?
|
| Ferritins | 1 | 2022 | 154 | 0.190 |
Why?
|
| DNA Helicases | 1 | 2024 | 451 | 0.190 |
Why?
|
| Up-Regulation | 2 | 2018 | 2457 | 0.190 |
Why?
|
| Cell Cycle Proteins | 4 | 2023 | 2128 | 0.190 |
Why?
|
| Perforin | 1 | 2021 | 52 | 0.190 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2023 | 289 | 0.190 |
Why?
|
| Antimetabolites | 1 | 2021 | 77 | 0.190 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 215 | 0.190 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 85 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 484 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2021 | 76 | 0.190 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2021 | 48 | 0.190 |
Why?
|
| Retreatment | 3 | 2019 | 447 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 2 | 2023 | 267 | 0.190 |
Why?
|
| Comorbidity | 3 | 2017 | 2435 | 0.190 |
Why?
|
| Multivariate Analysis | 6 | 2021 | 4352 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2023 | 529 | 0.180 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 58 | 0.180 |
Why?
|
| Transcriptome | 4 | 2023 | 1940 | 0.180 |
Why?
|
| Sarcoma, Myeloid | 1 | 2021 | 94 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 122 | 0.180 |
Why?
|
| Piperidines | 2 | 2024 | 1090 | 0.180 |
Why?
|
| Quinuclidines | 1 | 2020 | 47 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 347 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2022 | 118 | 0.180 |
Why?
|
| Child | 14 | 2024 | 30401 | 0.180 |
Why?
|
| Infusions, Intravenous | 3 | 2019 | 1439 | 0.180 |
Why?
|
| Lymphocyte Count | 2 | 2018 | 485 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 65 | 0.180 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 275 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 137 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2024 | 1657 | 0.180 |
Why?
|
| Safety | 2 | 2018 | 466 | 0.180 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2020 | 43 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 212 | 0.170 |
Why?
|
| Hydrazines | 2 | 2018 | 214 | 0.170 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2020 | 58 | 0.170 |
Why?
|
| Sezary Syndrome | 1 | 2021 | 167 | 0.170 |
Why?
|
| Forecasting | 1 | 2022 | 705 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2024 | 1180 | 0.170 |
Why?
|
| Myelitis, Transverse | 1 | 2019 | 13 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2018 | 1618 | 0.170 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2019 | 22 | 0.170 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 410 | 0.170 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 122 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 7817 | 0.160 |
Why?
|
| Biological Products | 1 | 2023 | 316 | 0.160 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 88 | 0.160 |
Why?
|
| Central Nervous System | 1 | 2021 | 457 | 0.160 |
Why?
|
| Hemorrhage | 2 | 2023 | 744 | 0.160 |
Why?
|
| Optic Neuritis | 1 | 2019 | 39 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 325 | 0.160 |
Why?
|
| Dyspnea | 1 | 2022 | 421 | 0.160 |
Why?
|
| Genes, cdc | 1 | 2018 | 84 | 0.160 |
Why?
|
| Carbolines | 1 | 2018 | 30 | 0.160 |
Why?
|
| Indolizines | 1 | 2018 | 46 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2020 | 12219 | 0.160 |
Why?
|
| Patient Dropouts | 1 | 2019 | 84 | 0.160 |
Why?
|
| Pyridinium Compounds | 1 | 2018 | 64 | 0.160 |
Why?
|
| Alleles | 3 | 2020 | 2598 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 3 | 2024 | 1469 | 0.160 |
Why?
|
| Sepsis | 1 | 2024 | 688 | 0.150 |
Why?
|
| Cyclic N-Oxides | 1 | 2018 | 97 | 0.150 |
Why?
|
| Psychology | 1 | 2018 | 83 | 0.150 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 97 | 0.150 |
Why?
|
| Leukemia, B-Cell | 2 | 2016 | 114 | 0.150 |
Why?
|
| STAT Transcription Factors | 2 | 2015 | 80 | 0.150 |
Why?
|
| Necrosis | 2 | 2020 | 604 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 329 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 508 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 565 | 0.150 |
Why?
|
| Quinolines | 1 | 2021 | 402 | 0.150 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2018 | 125 | 0.150 |
Why?
|
| Chromatin | 1 | 2023 | 1049 | 0.150 |
Why?
|
| Risk | 5 | 2021 | 1950 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2024 | 6230 | 0.150 |
Why?
|
| Benzoates | 1 | 2018 | 130 | 0.150 |
Why?
|
| Mycoses | 1 | 2021 | 396 | 0.150 |
Why?
|
| Genes, ras | 2 | 2022 | 681 | 0.150 |
Why?
|
| Thorax | 1 | 2019 | 230 | 0.150 |
Why?
|
| Interferon-alpha | 2 | 2022 | 961 | 0.150 |
Why?
|
| Haptoglobins | 1 | 2017 | 27 | 0.140 |
Why?
|
| Naphthyridines | 1 | 2017 | 43 | 0.140 |
Why?
|
| Leukocyte Count | 2 | 2018 | 738 | 0.140 |
Why?
|
| Thiazoles | 2 | 2021 | 725 | 0.140 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 148 | 0.140 |
Why?
|
| Exotoxins | 1 | 2017 | 76 | 0.140 |
Why?
|
| Karyopherins | 1 | 2018 | 134 | 0.140 |
Why?
|
| Consensus | 2 | 2023 | 1115 | 0.140 |
Why?
|
| Galectin 3 | 1 | 2018 | 132 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 4 | 2022 | 508 | 0.140 |
Why?
|
| Alemtuzumab | 1 | 2017 | 208 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 2574 | 0.140 |
Why?
|
| Interleukin-10 | 1 | 2019 | 482 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2017 | 102 | 0.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2024 | 1331 | 0.140 |
Why?
|
| Consolidation Chemotherapy | 4 | 2020 | 154 | 0.140 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 183 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1053 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 183 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 474 | 0.130 |
Why?
|
| Antibody Specificity | 1 | 2017 | 340 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2021 | 1436 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2024 | 1730 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 237 | 0.130 |
Why?
|
| Ligands | 1 | 2018 | 1057 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 430 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2017 | 330 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 229 | 0.130 |
Why?
|
| Methylation | 1 | 2017 | 626 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2017 | 296 | 0.130 |
Why?
|
| Chromosome Banding | 1 | 2016 | 280 | 0.130 |
Why?
|
| Microbiota | 1 | 2022 | 544 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2017 | 253 | 0.130 |
Why?
|
| Blood Cell Count | 1 | 2016 | 234 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 642 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2018 | 2853 | 0.130 |
Why?
|
| Research Design | 2 | 2021 | 1580 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 228 | 0.130 |
Why?
|
| Busulfan | 2 | 2020 | 786 | 0.130 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 9042 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 1101 | 0.120 |
Why?
|
| Erythrocyte Indices | 1 | 2014 | 24 | 0.120 |
Why?
|
| Child, Preschool | 7 | 2021 | 16943 | 0.120 |
Why?
|
| Liver | 1 | 2005 | 3123 | 0.120 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2015 | 74 | 0.120 |
Why?
|
| Pyridines | 3 | 2022 | 1311 | 0.120 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 454 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 662 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 742 | 0.120 |
Why?
|
| Anemia, Pernicious | 1 | 2014 | 12 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2020 | 755 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1728 | 0.110 |
Why?
|
| Vitamin B 12 | 1 | 2014 | 76 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 641 | 0.110 |
Why?
|
| Mice | 10 | 2024 | 36006 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 879 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 5744 | 0.110 |
Why?
|
| Prodrugs | 1 | 2015 | 226 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2019 | 1378 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2018 | 684 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2014 | 340 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2016 | 810 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 1094 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2018 | 698 | 0.110 |
Why?
|
| Thrombosis | 1 | 2019 | 751 | 0.110 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2017 | 445 | 0.110 |
Why?
|
| Splicing Factor U2AF | 2 | 2023 | 44 | 0.110 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2012 | 22 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5566 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2015 | 356 | 0.100 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2023 | 84 | 0.100 |
Why?
|
| Infant | 5 | 2022 | 13887 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2021 | 2287 | 0.100 |
Why?
|
| Fibrosis | 1 | 2015 | 746 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2014 | 483 | 0.100 |
Why?
|
| Patient Safety | 1 | 2018 | 655 | 0.100 |
Why?
|
| Hypoxia | 1 | 2015 | 468 | 0.100 |
Why?
|
| Feces | 3 | 2022 | 865 | 0.100 |
Why?
|
| Karyotyping | 3 | 2024 | 1064 | 0.100 |
Why?
|
| Sequence Deletion | 1 | 2014 | 915 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 879 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 609 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 196 | 0.090 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 341 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2012 | 413 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 668 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2014 | 582 | 0.090 |
Why?
|
| Down Syndrome | 1 | 2013 | 227 | 0.090 |
Why?
|
| Quality of Life | 3 | 2023 | 4745 | 0.090 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 4890 | 0.090 |
Why?
|
| Asparaginase | 3 | 2016 | 186 | 0.090 |
Why?
|
| RNA Splicing Factors | 2 | 2023 | 154 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 605 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2023 | 7788 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 731 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 2198 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 1500 | 0.080 |
Why?
|
| Benzamides | 1 | 2015 | 1882 | 0.080 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 910 | 0.080 |
Why?
|
| Monosomy | 2 | 2022 | 98 | 0.080 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2019 | 79 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 2155 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 4391 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1574 | 0.080 |
Why?
|
| DNA Modification Methylases | 2 | 2022 | 176 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 2471 | 0.080 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2023 | 382 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2021 | 1241 | 0.070 |
Why?
|
| Cytogenetics | 2 | 2020 | 152 | 0.070 |
Why?
|
| Abscess | 1 | 2008 | 192 | 0.070 |
Why?
|
| Melphalan | 2 | 2020 | 875 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2022 | 1364 | 0.070 |
Why?
|
| Piperazines | 1 | 2015 | 2151 | 0.070 |
Why?
|
| Neurocysticercosis | 1 | 2005 | 26 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 4193 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2016 | 6488 | 0.060 |
Why?
|
| Rifampin | 1 | 2007 | 220 | 0.060 |
Why?
|
| Injections, Spinal | 2 | 2017 | 275 | 0.060 |
Why?
|
| Triazoles | 2 | 2021 | 629 | 0.060 |
Why?
|
| Antifungal Agents | 2 | 2021 | 876 | 0.060 |
Why?
|
| United States | 2 | 2019 | 16036 | 0.060 |
Why?
|
| Lamivudine | 1 | 2004 | 28 | 0.060 |
Why?
|
| Vancomycin | 1 | 2007 | 292 | 0.060 |
Why?
|
| Benzeneacetamides | 1 | 2024 | 42 | 0.060 |
Why?
|
| Chloroquine | 1 | 2004 | 61 | 0.060 |
Why?
|
| Thiadiazoles | 1 | 2024 | 61 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2017 | 835 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2024 | 41 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2017 | 1432 | 0.060 |
Why?
|
| Georgia | 1 | 2023 | 53 | 0.060 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2023 | 53 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2021 | 2035 | 0.060 |
Why?
|
| Gene Expression | 3 | 2018 | 3688 | 0.060 |
Why?
|
| Activin Receptors, Type I | 1 | 2023 | 58 | 0.060 |
Why?
|
| Laparotomy | 1 | 2005 | 228 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 690 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2023 | 208 | 0.060 |
Why?
|
| Bone Marrow Diseases | 1 | 2024 | 187 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2023 | 162 | 0.050 |
Why?
|
| Neutropenia | 2 | 2019 | 1001 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 3924 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 2286 | 0.050 |
Why?
|
| Income | 1 | 2023 | 230 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2013 | 2973 | 0.050 |
Why?
|
| Oxazoles | 1 | 2022 | 62 | 0.050 |
Why?
|
| North America | 1 | 2023 | 341 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 240 | 0.050 |
Why?
|
| Base Pair Mismatch | 1 | 2021 | 82 | 0.050 |
Why?
|
| Granzymes | 1 | 2021 | 95 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 267 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2021 | 206 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2021 | 179 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2022 | 153 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2023 | 390 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 2334 | 0.050 |
Why?
|
| Chimerism | 1 | 2021 | 65 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2021 | 173 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2020 | 2348 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 352 | 0.050 |
Why?
|
| Sex Factors | 2 | 2017 | 2202 | 0.050 |
Why?
|
| Azoles | 1 | 2021 | 48 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 275 | 0.050 |
Why?
|
| Medical Futility | 1 | 2021 | 56 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 3544 | 0.050 |
Why?
|
| Texas | 3 | 2021 | 6434 | 0.050 |
Why?
|
| Cytokines | 2 | 2022 | 2837 | 0.050 |
Why?
|
| Arthralgia | 1 | 2021 | 97 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2020 | 435 | 0.050 |
Why?
|
| Benzylamines | 1 | 2020 | 101 | 0.050 |
Why?
|
| Leukocytes | 1 | 2022 | 426 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2024 | 1650 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 3512 | 0.040 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 13989 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 179 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2023 | 706 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2022 | 317 | 0.040 |
Why?
|
| Genomics | 2 | 2022 | 2830 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 384 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2020 | 119 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 117 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2021 | 629 | 0.040 |
Why?
|
| Autoantigens | 1 | 2021 | 248 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 716 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 361 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 8089 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2020 | 200 | 0.040 |
Why?
|
| Cell Division | 1 | 2023 | 2711 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 2020 | 103 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2021 | 441 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 1666 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 251 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2023 | 815 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2023 | 621 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 246 | 0.040 |
Why?
|
| Diploidy | 1 | 2018 | 116 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2018 | 55 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 794 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2021 | 832 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 1005 | 0.040 |
Why?
|
| Pyrroles | 1 | 2022 | 592 | 0.040 |
Why?
|
| Receptors, KIR | 1 | 2018 | 64 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 28 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2019 | 136 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2018 | 101 | 0.040 |
Why?
|
| Liposomes | 1 | 2020 | 710 | 0.040 |
Why?
|
| Nucleotides | 1 | 2018 | 175 | 0.040 |
Why?
|
| Galectins | 1 | 2018 | 73 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 1021 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2018 | 220 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2017 | 86 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 544 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2017 | 85 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2018 | 316 | 0.040 |
Why?
|
| Calreticulin | 1 | 2018 | 87 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 540 | 0.040 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 16 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2018 | 167 | 0.040 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2017 | 59 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2018 | 150 | 0.040 |
Why?
|
| Exanthema | 1 | 2019 | 210 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 659 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 1851 | 0.040 |
Why?
|
| Abnormal Karyotype | 1 | 2017 | 101 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 406 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2018 | 301 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2017 | 237 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2018 | 312 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2018 | 631 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1051 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 150 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 344 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2019 | 377 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2021 | 1755 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 293 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2020 | 621 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 349 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 93 | 0.030 |
Why?
|
| Saliva | 1 | 2017 | 238 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 1372 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2021 | 1571 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 177 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 186 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1555 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 120 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2022 | 1254 | 0.030 |
Why?
|
| Glycolysis | 1 | 2018 | 534 | 0.030 |
Why?
|
| Codon | 1 | 2015 | 262 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 201 | 0.030 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2015 | 40 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 2015 | 50 | 0.030 |
Why?
|
| Myelin Basic Protein | 1 | 2015 | 96 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 1482 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 247 | 0.030 |
Why?
|
| Metagenome | 1 | 2016 | 193 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2017 | 320 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 277 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1849 | 0.030 |
Why?
|
| Enterocolitis | 1 | 2015 | 48 | 0.030 |
Why?
|
| Transaminases | 1 | 2014 | 82 | 0.030 |
Why?
|
| Thioguanine | 1 | 2014 | 70 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 289 | 0.030 |
Why?
|
| Nitroimidazoles | 1 | 2015 | 107 | 0.030 |
Why?
|
| Mercaptopurine | 1 | 2014 | 131 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 1405 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 371 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 3088 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1468 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2017 | 414 | 0.030 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2014 | 53 | 0.030 |
Why?
|
| DNA Repair | 1 | 2021 | 1912 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 9093 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 2532 | 0.030 |
Why?
|
| Bilirubin | 1 | 2014 | 224 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 274 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 3526 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2021 | 2138 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 908 | 0.030 |
Why?
|
| Trisomy | 1 | 2014 | 240 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 399 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2020 | 931 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 1972 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 1212 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2018 | 1003 | 0.030 |
Why?
|
| Bacteria | 1 | 2017 | 652 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2023 | 4191 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 780 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 5180 | 0.020 |
Why?
|
| HIV Infections | 1 | 2004 | 2156 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2017 | 1486 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 959 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 1259 | 0.020 |
Why?
|
| Nausea | 1 | 2013 | 540 | 0.020 |
Why?
|
| Time Factors | 2 | 2017 | 13116 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 271 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2015 | 724 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 1313 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1603 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2051 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 2043 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 744 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2018 | 4984 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7929 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 1284 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2017 | 969 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 7463 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6208 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 1589 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 5499 | 0.020 |
Why?
|
| Spinal Diseases | 1 | 2008 | 131 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4998 | 0.020 |
Why?
|
| Central America | 1 | 2005 | 29 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8587 | 0.020 |
Why?
|
| Animal Husbandry | 1 | 2005 | 47 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2005 | 97 | 0.020 |
Why?
|
| Mexico | 1 | 2005 | 275 | 0.020 |
Why?
|
| Travel | 1 | 2005 | 200 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2005 | 334 | 0.010 |
Why?
|
| Bacteremia | 1 | 2008 | 722 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 1610 | 0.010 |
Why?
|